Clinical trial · Observational
Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab
Observational Cohort Study to Characterize the Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab
NCT03200977CI-TRIAL-00087713completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
An observational database analysis, using existing data of patients diagnosed with Classical Hodgkin Lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Non-Interventional | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Exposed to nivolumab prior to allogeneic HCT
- description
- patients who were treated with nivolumab-based regimen prior to an allogeneic HCT
- interventionNames
- Other: Non-Interventional
- label
- Unexposed to nivolumab prior to allogeneic HCT
- description
- patients who were not treated with nivolumab-based regimen prior to an allogeneic HCT
- interventionNames
- Other: Non-Interventional
Primary outcomes (1)
- measure
- Treatment-Related Mortality (TRM)
- timeFrame
- At 6 months after an allogeneic HCT
- description
- Treatment-Related Mortality at 6 months after an allogeneic Hemaetopoietic Cell Transplantation (HCT) among patients with cHL who were previously treated with nivolumab
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age greater than or equal to18 years; * First allogeneic HCT for cHL; * Patients with prior autologous HCT for cHL; * Any conditioning regimen, graft source or donor type. * For the primary analysis additional criterion includes prior exposure to nivolumab for treatment of cHL immediately prior to the allogeneic HCT, as defined as nivolumab used alone or in combination with other agents and used as the last line of therapy prior to an allogeneic HCT with the interval between the last dose of nivolumab and start of the conditioning regimen no longer than 12 months. Exclusion Criteria: * Patients with nodular lymphocyte-predominant HL * Previous chimeric antigen receptor T-cell therapy or other genetically modified cellular product
References
Publications (0)
Data not yet available
No reference posted for this study.